發(fā)布時間：2018-05-05 04:10

  本文選題：定量蛋白質(zhì)組學(xué) + 阿爾茨海默癥��； 參考：《中國科學(xué):化學(xué)》2014年05期

【摘要】：阿爾茨海默癥(Alzheimer’s disease,AD)是一種以行為功能紊亂、神經(jīng)元逐漸丟失為主要特征的退行性疾病,它對人類的生活質(zhì)量和生命造成了極大威脅.隨著臨床標(biāo)志物(clinical biomarker)概念的提出和定量蛋白質(zhì)組學(xué)的研究進(jìn)展,對于促進(jìn)AD病診斷、監(jiān)測疾病進(jìn)程以及評估現(xiàn)有治療手段等方面提出了新的思路,但臨床標(biāo)志物的遴選存在許多技術(shù)難點.定量蛋白質(zhì)組學(xué)利用其能夠快速分析和準(zhǔn)確鑒定疾病中功能蛋白的特點,大大提高了遴選臨床標(biāo)志物的效率.本文綜述了定量蛋白質(zhì)組學(xué)技術(shù)在遴選AD中臨床標(biāo)志物的應(yīng)用進(jìn)展.
[Abstract]:Alzheimer's disease (AD) is a degenerative disease characterized by behavioral disorder and neuron loss, which poses a great threat to the quality of life and life of human beings. With the concept of clinical biomarker and the research progress of quantitative proteomics, new ideas have been put forward to promote the diagnosis of AD disease, monitor the disease process and evaluate the existing treatment methods. However, there are many technical difficulties in the selection of clinical markers. Quantitative proteomics can rapidly analyze and accurately identify the characteristics of functional proteins in diseases, which greatly improves the efficiency of selecting clinical markers. This article reviews the application of quantitative proteomics in the selection of clinical markers in AD.
【作者單位】： 蛋白質(zhì)與植物基因研究國家重點實驗室;北京大學(xué)生命科學(xué)學(xué)院;
【基金】：國家自然科學(xué)基金(31270872) 國家重大研究計劃(2010CB912203,2011CB915504)的資助
【分類號】：R749.16;Q51-3

【共引文獻(xiàn)】

相關(guān)期刊論文 前6條

1 LI WenWen;WANG QuanHui;CHEN JianJun;ZHOU Jian;ZHOU XinYu;XIE Peng;;A multiple-reaction-monitoring mass spectrometric method for simultaneous quantitative analysis of five plasma apolipoproteins[J];Science China(Chemistry);2014年05期

2 呂俊鳥;鄭良s，

本文編號：1846128